GEN-PIROXICAM - CAP 20MG CAPSULE
Land: Canada
Taal: Engels
Bron: Health Canada
Productkenmerken
(SPC)
12-10-2016
Sommige documenten voor dit product zijn momenteel niet beschikbaar, u kunt een verzoek sturen naar onze klantenservice en we zullen u hiervan op de hoogte stellen zodra we ze kunnen verkrijgen.
Verzend verzoek.
Verzend verzoek.
Werkstoffen:
PIROXICAM
Beschikbaar vanaf:
GENPHARM ULC
ATC-code:
M01AC01
INN (Algemene Internationale Benaming):
PIROXICAM
Dosering:
20MG
farmaceutische vorm:
CAPSULE
Samenstelling:
PIROXICAM 20MG
Toedieningsweg:
ORAL
Eenheden in pakket:
100/500
Prescription-type:
Prescription
Therapeutisch gebied:
OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS
Product samenvatting:
Active ingredient group (AIG) number: 0114612001; AHFS:
Autorisatie-status:
CANCELLED POST MARKET
Autorisatie datum:
2010-08-04
Productkenmerken
_ _
_ _
_Page 1 of 35_
PRODUCT MONOGRAPH
PR
GEN-PIROXICAM
(Piroxicam, USP)
10 and 20 mg Capsules
Nonsteroidal Anti-inflammatory Drug (NSAID)
Genpharm ULC
85 Advance Road
Etobicoke, ON
Canada
M8Z 2S6
DATE OF REVISION:
December 01, 2009
CONTROL NO: 129679
_ _
_ _
_Page 2 of 35_
Table of Contents
PART I: HEALTH PROFESSIONAL
INFORMATION.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL
USE..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND
PRECAUTIONS..................................................................................5
ADVERSE
REACTIONS..................................................................................................14
DRUG INTERACTIONS
..................................................................................................19
DOSAGE AND
ADMINISTRATION..............................................................................22
OVERDOSAGE
................................................................................................................24
ACTION AND CLINICAL PHARMACOLOGY
............................................................24
STORAGE AND
STABILITY..........................................................................................25
SPECIAL HANDLING INSTRUCTIONS
.......................................................................25
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................25
PART II: SCIENTIFIC INFORMATION
...............................................................................27
PHARMACEUTICAL
INFORMATION..........................................................................27
CLINICAL
TRIALS..........................................................................................................27
DETAIL
Lees het volledige document
